Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update May 14, 2024
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day May 8, 2024
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 May 7, 2024
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update Mar 27, 2024
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 Mar 20, 2024
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Mar 4, 2024
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Feb 7, 2024
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study Jan 30, 2024
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million Jan 25, 2024
